U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H44N8O3
Molecular Weight 552.7115
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GILTERITINIB

SMILES

CCC1=C(NC2CCOCC2)N=C(NC3=CC=C(N4CCC(CC4)N5CCN(C)CC5)C(OC)=C3)C(=N1)C(N)=O

InChI

InChIKey=GYQYAJJFPNQOOW-UHFFFAOYSA-N
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

HIDE SMILES / InChI

Description

Gilteritinib, also known as ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In in vitro, among the 78 tyrosine kinases tested, Gilteritinib inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. Gilteritinib inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. Gilteritinib decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. In previous preclinical studies, gilteritinib has demonstrated superior antitumor effects when given in combination with AraC and either DNR or IDR compared with combination chemotherapy. In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

CNS Activity

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XOSPATA
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In Vivo Use Guide
120 mg orally once-daily
Route of Administration: Oral
In Vitro Use Guide
Gilteritinib inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM
Name Type Language
GILTERITINIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
GILTERITINIB [USAN]
Common Name English
ASP2215
Code English
GILTERITINIB [INN]
Common Name English
GILTERITINIB [WHO-DD]
Common Name English
2-PYRAZINECARBOXAMIDE, 6-ETHYL-3-((3-METHOXY-4-(4-(4-METHYL-1-PIPERAZINYL)-1-PIPERIDINYL)PHENYL)AMINO)-5-((TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-
Systematic Name English
ASP-2215
Code English
Code System Code Type Description
CAS
1254053-43-4
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY
INN
10048
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY
NCI_THESAURUS
C116722
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY
PUBCHEM
49803313
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY SWITZERF
ChEMBL
CHEMBL3301622
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY
EVMPD
SUB177203
Created by admin on Tue Mar 06 13:28:27 UTC 2018 , Edited by admin on Tue Mar 06 13:28:27 UTC 2018
PRIMARY